EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients USA – English Israel – English
A novel approach to treating skin toxicities caused by EGFRi, based on a decade of research by leading Israeli cancer researchers JERUSALEM, June 8, 2023 /PRNewswire/ — Hadasit, and Yissum, has spun off EMRIS Pharma in collaboration with NGT Healthcare2 VC. EMRIS Pharma is pioneering novel small molecule-based topical compounds that can improve both quality of … Read more